

References

L-235

1. Cohen BH, Chinnery PG, Copeland WC (Updated December 18, 2014). POLG Related Disorders. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright University of Washington, Seattle. 1993-2016.
2. Cohen BH, Naviaux RK. The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders. *Methods*. 2010;51:364-373.
3. Goldstein AC, Bhatia P, Vento JM. Mitochondrial Disease in Childhood: Nuclear Encoded. *Neurotherapeutics*. 2013;10:212–226.
4. Horvath R, Hudson G, Ferrari G. Phenotypic spectrum associated with mutations of the mitochondrial polymerase γ gene. *Brain*. 2006;129:1674-1684.
5. Van Goethem G, Mercelis R, Löfgren A, Seneca S, Ceuterick C, Martin JJ, et al. Patient homozygous for a recessive POLG mutation presents with features of MERRF. *Neurology*. 2003;61:1811-1813.
6. Nguyen KV, Sharief FS, Chan SS, Copeland WC, Naviaux RK. Molecular diagnosis of Alpers syndrome. *J Hepatol*. 2006;45:108-116.
7. Saneto RP, Lee IC, Koenig MK, Bao X, Weng SW, Naviaux RK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. *Seizure*. 2010;19:140-146.
8. Bicknese AR, May W, Hickey WF, Dodson WE. Early childhood hepatocerebral degeneration misdiagnosed as valproate hepato- toxicity. *Ann Neurol*. 1992;32:767-775.
9. Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. *Hum Mutat*. 2008;10150-10172.
10. Milone M, Massie R. Polymerase gamma 1 mutations: clinical correlations. *Neurologist*. 2010. Mar;16(2):84-91.
11. Fadic R, Russell JA, Vedanarayanan VV, Lehar M, Kuncl RW, Johns DR. Sensory ataxic neuropathy as the presenting feature of a novel mitochondrial disease. *Neurology*. 1997;49:239-245.
12. Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. *Nat Genet*. 2001;28:211–2.
13. de Vries MC, Rodenburg RJ, Morava E, Lammens M, van den Heuvel LP, Korenke GC, Smeitink JA. Normal biochemical analysis of the oxidative phosphorylation (OXPHOS) system in a child with POLG mutations: a cautionary note. *J Inherit Metab Dis*. 2008;31 Suppl 2:S299–302.

14. Parikh, S. et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. *Genetics in Medicine*. 2015;17(9):689-701.
15. Van de Warrenburg BPC, van Gaalen J, Boesch S, et al. EFNS/ENS 2014 EFNS/ENS consensus on the diagnosis and management of chronic ataxias in adulthood. *European Journal of Neurology*. 2014;21:552-562.
16. FDA label: Depakote ER.